Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

ZTS

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

ZTS

AI Research Report

Powered by Claude

Ready to analyze ZTS

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

C+
Stonvex Quant Grade
50.0/ 100
Rank-normalised composite of 6 factors, updated every 60 seconds.
Volume
C+
50 / 100

Today's volume vs prior session average.

Volatility
C+
50 / 100

Absolute daily price move vs peers.

News Flow
C+
50 / 100

24h article count relative to the universe.

Sentiment
C+
50 / 100

AI-classified polarity of recent news.

Dollar Flow
C+
50 / 100

Today's dollar turnover (volume × VWAP).

Relative Strength
C+
50 / 100

Signed daily return vs the rest of the universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Similar stocks

View all Healthcare →
LLY
Eli Lilly
$810.50
+2.30%
UNH
UnitedHealth
$485.20
-2.51%
NVO
Novo Nordisk
—
—
JNJ
Johnson & Johnson
—
—
TMO
Thermo Fisher
—
—
WELL
Welltower
—
—
Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

📅 Earnings in 23d (May 7)

Analyst Consensus

Buy
Based on 25 analysts
Period: 2026-04-01
15 Buy (60%)10 Hold (40%)0 Sell (0%)
Rating Distribution
Strong Buy
6
Buy
9
Hold
10
Sell
0
Strong Sell
0
Trend
2026-04
15/10/0
2026-03
16/9/0
2026-02
16/8/0
2026-01
17/7/0
Zoetis Inc

Zoetis Inc

Pharmaceuticals·NEW YORK STOCK EXCHANGE, INC.·US·IPO 2013-02-01
  • Yahoo·1d ago

    Wall Street Analysts See a 28.23% Upside in Zoetis (ZTS): Can the Stock Really Move This High?

    The mean of analysts' price targets for Zoetis (ZTS) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • Yahoo·1d ago

    Why Investors Need to Take Advantage of These 2 Medical Stocks Now

    The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

  • Yahoo·1d ago

    The Bull Case For Neogen (NEOG) Could Change Following Q3 Loss, Guidance Hike, Genomics Sale News

    Neogen Corporation recently reported fiscal third-quarter 2026 results, with revenue of US$211.2 million versus US$221.0 million a year earlier and a net loss of US$17.0 million, while also modestly raising full-year 2026 revenue guidance to a range of about US$857.0 million to US$860.0 million. Alongside tighter cost control and solid Food Safety performance, Neogen is reshaping its portfolio through divestitures and leadership changes, including appointing Jennifer Evans Stacey as Chief...

  • Yahoo·4d ago

    Zoetis (ZTS) Declines More Than Market: Some Information for Investors

    The latest trading day saw Zoetis (ZTS) settling at $117.86, representing a -1.78% change from its previous close.

  • SeekingAlpha·4d ago

    Dividend Champion, Contender, And Challenger Highlights: Week Of April 12

    A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full list here.

  • Benzinga·5d ago

    March Inflation Set For Biggest Jump Since June 2022 — When CPI Spikes, These Stocks Fall

    Trump, in January, said "inflation has been defeated." Wall Street is now bracing for a 0.9% monthly CPI surge — the steepest since June 2022.

  • SeekingAlpha·5d ago

    SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For April 2026

    The 4-Factor Dividend Growth Strategy outperformed SCHD with a 12.48% annualized return vs. SCHD’s 10.79% since inception. Learn more about the strategy here.

  • Yahoo·6d ago

    How Investors May Respond To Zoetis (ZTS) Deepening Its Biologics Focus After World Vaccine Congress Update

    Zoetis Inc. recently presented at the World Vaccine Congress Washington 2026 at the Walter E. Washington Convention Center, where Senior VP of Global Biologics R&D Mahesh Kumar highlighted the company’s latest vaccine research and development efforts. This appearance underscores how Zoetis is pairing its biologics and vaccine innovation with previously reported broad-based operational growth driven by its newer companion animal therapies and parasiticide franchises. We’ll now explore how...

  • View all news →

Recent insider activity

View all →
  • 4FORM 4
    Yesterday
  • 4FORM 4
    Yesterday
  • 4FORM 4
    Yesterday
  • 4FORM 4
    Yesterday
  • 4FORM 4
    Yesterday
NEW YORK STOCK EXCHANGE, INC.After-hours
Zoetis Inc
Pharmaceuticals
$121.11
$1.03 (+0.86%)
After-hrs · vs prev close $120.08
Open
$119.45
Prev close
$120.08
Day range
$118.60 – $121.19
52W range
$113.29 – $172.23
Mkt cap
$49.79B
P/E
18.8
EPS
$6.02
Beta
0.95

Fundamentals

Valuation
Market Cap
$49.79B
P/E (TTM)
18.75S&P avg ~22
P/S (TTM)
5.29S&P avg ~2.8
P/B
16.65S&P avg ~4.5
P/FCF
21.96S&P avg ~26
EPS (TTM)
$6.02
Book/sh
$7.84
Cash/sh
$5.44
Profitability
Gross Margin
71.89%avg ~45%
Operating Margin
35.49%avg ~15%
Net Margin
28.23%avg ~12%
ROE
58.23%avg ~18%
ROA
18.06%avg ~7%
ROI
22.45%
Payout Ratio
33.26%
FCF/sh
—
Growth & Health
Rev Growth YoY
2.28%
Rev Growth 5Y
7.24%
EPS Growth YoY
10.17%
EPS Growth 5Y
11.97%
Current Ratio
—
Quick Ratio
1.94
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.95
52W High
$172.23
52W Low
$113.29
Avg Vol (10D)
2.72M
Avg Vol (3M)
4.70M
Div Yield
1.64%
Div/sh (TTM)
—
Analyst
Buy (25)
Price Performance
5D+2.81%
MTD+1.58%
3M-5.34%
6M-17.39%
YTD-4.56%
1Y-18.31%

Factor Grades

View details →
B-
Overall score: 61/100
C
Valuation
C+
Growth
A
Profitability
D-
Momentum
A-
Financial Health